Corient Private Wealth LP lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: RE

Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage

Regeneron Pharmaceuticals NASDAQ: REGN outlined growth opportunities for Dupixent, pipeline catalyst

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conf

SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Re

NEW YORK--(BUSINESS WIRE)---- $REGN #ClassAction--Faruqi & Faruqi, LLP, a leading national securitie

[url="]Schall, Brown and Schwartz LLP[/url] (“SBS”), a national shareholder rights litigation fi

LOS ANGELES--(BUSINESS WIRE)---- $REGN--REGN Investors Have Opportunity to Lead Regeneron Pharmaceut

LOS ANGELES, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national sha

New class action for Regeneron (REGN) urges investors to seek recovery for alleged securities fraud

REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses H

SAN DIEGO, Sept. 13, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP  announces that purchaser

San Diego, California--(Newsfile Corp. - September 12, 2026) - Robbins Geller Rudman & Dowd LLP anno

SAN FRANCISCO, Sept. 12, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors i

Regeneron Pharmaceuticals NASDAQ: REGN executives outlined plans for continued growth across its com

San Francisco, California--(Newsfile Corp. - September 11, 2026) - Hagens Berman Sobol Shapiro LLP a

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suf

SAN DIEGO, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purcha

SAN DIEGO--(BUSINESS WIRE)---- $REGN #REGN--The case alleges Regeneron and its top executives made f

SAN FRANCISCO, Sept. 10, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Re

HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 4.59%

https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidem

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.17%

Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven

Bill Ackman gifted $400 million of his Pershing Square stake to a brain research foundation after hi

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration

Sanofi withdrew its Dupixent application for bullous pemphigoid on June 24, 2026, due to unresolved

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.69%

China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s

https://www.newswire.ca/news-releases/libtayo-r-cemiplimab-for-injection-receives-health-canada-appr

Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and r

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Secto

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a

Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a O

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-W

Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $14.29 per share which beat t

Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety da

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and r

For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as &#34

Piper Sandler analyst Biren Amin maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overwei

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Secto

Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a

Top Wall Street analysts upgraded FSLR, META, WM, NET, and REGN stocks. Check out analyst ratings pa

Benchmark analyst Robert Wasserman upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Hold to